Our top pick for
Building a portfolio
Arrowhead Pharmaceuticals, Inc is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Arrowhead Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around USD$79.8 million.
|52-week range||USD$30.83 - USD$92.6|
|50-day moving average||USD$72.5177|
|200-day moving average||USD$68.893|
|Wall St. target price||USD$91.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.092|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Arrowhead Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arrowhead Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arrowhead Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 479x. In other words, Arrowhead Pharmaceuticals shares trade at around 479x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Arrowhead Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.9 million.
The EBITDA is a measure of a Arrowhead Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$79.8 million|
|Gross profit TTM||USD$88 million|
|Return on assets TTM||-12.92%|
|Return on equity TTM||-21.51%|
|Market capitalisation||USD$6.7 billion|
TTM: trailing 12 months
There are currently 5.1 million Arrowhead Pharmaceuticals shares held short by investors – that's known as Arrowhead Pharmaceuticals's "short interest". This figure is 0.2% down from 5.1 million last month.
There are a few different ways that this level of interest in shorting Arrowhead Pharmaceuticals shares can be evaluated.
Arrowhead Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arrowhead Pharmaceuticals shares currently shorted divided by the average quantity of Arrowhead Pharmaceuticals shares traded daily (recently around 886270.1208981). Arrowhead Pharmaceuticals's SIR currently stands at 5.79. In other words for every 100,000 Arrowhead Pharmaceuticals shares traded daily on the market, roughly 5790 shares are currently held short.
However Arrowhead Pharmaceuticals's short interest can also be evaluated against the total number of Arrowhead Pharmaceuticals shares, or, against the total number of tradable Arrowhead Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arrowhead Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Arrowhead Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0579% of the tradable shares (for every 100,000 tradable Arrowhead Pharmaceuticals shares, roughly 58 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arrowhead Pharmaceuticals.
Find out more about how you can short Arrowhead Pharmaceuticals stock.
We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.
Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.
Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $30.83 up to $92.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 1.267. This would suggest that Arrowhead Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.